重组组织型纤溶酶原激活剂治疗循环缺血性脑卒中的短期疗效及预后

目的 探讨阿替普酶溶栓治疗前、后循环急性脑梗死的临床效果以及预后的差异性.方法 对134例接受阿替普酶溶栓治疗的前、后循环急性脑梗死患者临床资料进行回顾性研究,根据梗死类型分为前循环组85例,后循环组49例,统计溶栓后NIHSS评分和mRS评分、早期症状改善率、预后良好率、症状性颅内出血率以及病死率,评估前后循环溶栓的...

Short-term clinical efficacy and prognosis of recombinant tissue plasminogen activator in anterior-posterior circulation acute ischemic stroke

Objective To investigate the clinical effect and prognosis difference of recombinant tissue plasminogen activator (rt-PA) in intravenous thrombolysis for anterior-posterior circulation acute ischemic stroke(AIS). Methods The retrospective research was conducted in clinical data on 134 patients with anterior-posterior circulation AIS treated with rt-PA thrombolysis. According to infarction type, the patients were divided into anterior circulation group (ACI group, n=85), posterior circulation group (PCI group, n=49). NIHSS score and mRS score, early symptom improvement rate, good prognosis rate,symptomatic intracranial hemorrhage rate and mortality after thrombolysis were counted; and the clinical efficacy and safety of anterior-posterior circulation thrombolysis were assessed. Results After thrombolysis, NIHSS score and mRS score in PCI group were significantly lower than in ACI group (P<0.05). Conclusion Compared with anterior circulation infarction, the natural course of posterior circulation cerebral infarction is poor. And all patients can still benefit significantly if they were given rt-PA in time intravenous thrombolysis, and does not increase the bleeding risk.